McKesson Corporation $MCK Shares Acquired by Gordian Capital Singapore Pte Ltd

Gordian Capital Singapore Pte Ltd increased its stake in McKesson Corporation (NYSE:MCK) by 620.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,440 shares of the company’s stock after buying an additional 1,240 shares during the period. McKesson accounts for approximately 1.6% of Gordian Capital Singapore Pte Ltd’s portfolio, making the stock its 23rd largest position. Gordian Capital Singapore Pte Ltd’s holdings in McKesson were worth $1,181,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of McKesson by 0.5% in the fourth quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,262 shares of the company’s stock worth $1,855,000 after acquiring an additional 11 shares during the last quarter. Obsidian Personal Planning Solutions LLC raised its holdings in McKesson by 2.9% in the third quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock valued at $346,000 after buying an additional 12 shares during the period. LRI Investments LLC raised its holdings in McKesson by 12.1% in the fourth quarter. LRI Investments LLC now owns 111 shares of the company’s stock valued at $91,000 after buying an additional 12 shares during the period. Macroview Investment Management LLC raised its holdings in McKesson by 3.9% in the fourth quarter. Macroview Investment Management LLC now owns 322 shares of the company’s stock valued at $264,000 after buying an additional 12 shares during the period. Finally, Berkshire Asset Management LLC PA raised its holdings in McKesson by 4.6% in the third quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock valued at $227,000 after buying an additional 13 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Stock Down 1.1%

MCK opened at $767.06 on Tuesday. The firm has a market capitalization of $92.20 billion, a P/E ratio of 19.94, a P/E/G ratio of 1.28 and a beta of 0.31. The firm’s 50 day moving average is $804.38 and its 200-day moving average is $848.26. McKesson Corporation has a 52-week low of $637.00 and a 52-week high of $999.00.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Thursday, May 7th. The company reported $11.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.56 by $0.13. The company had revenue of $96.30 billion for the quarter, compared to analyst estimates of $101.35 billion. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The business’s quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter last year, the firm posted $10.12 earnings per share. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Equities analysts expect that McKesson Corporation will post 44.28 earnings per share for the current fiscal year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is currently 8.53%.

Wall Street Analyst Weigh In

Several research analysts recently commented on MCK shares. UBS Group raised their price target on shares of McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Friday, May 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $875.00 price target on shares of McKesson in a report on Friday, May 8th. Wells Fargo & Company cut their price target on shares of McKesson from $925.00 to $812.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Raymond James Financial set a $970.00 price target on shares of McKesson in a report on Thursday, March 5th. Finally, Barclays raised their price target on shares of McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $968.87.

Insider Activity

In related news, CAO Napoleon B. Rutledge, Jr. sold 133 shares of McKesson stock in a transaction on Friday, June 5th. The shares were sold at an average price of $764.00, for a total value of $101,612.00. Following the completion of the sale, the chief accounting officer owned 632 shares in the company, valued at approximately $482,848. The trade was a 17.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michele Lau sold 3,550 shares of McKesson stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total transaction of $2,701,869.50. Following the completion of the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at approximately $2,471,259.23. This trade represents a 52.23% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,893 shares of company stock worth $5,225,385 over the last 90 days. Company insiders own 0.08% of the company’s stock.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.